Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis
Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)
This was a 2-part study of dexpramipexole in patients with ALS. Part 1 was a randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, and clinical effects of oral administration of 3 dosage levels…
- Trial name
- CL201 (NCT00647296)
- Testing
- Dexpramipexole 50 mg/day, Dexpramipexole 150 mg/day, Dexpramipexole 300 mg/day
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis
The Effect of GCSF in the Treatment of ALS Patients
The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients.
- Trial name
- NCT01825551
- Testing
- Granulocyte Colony Stimulating Factor
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
Amyotrophic Lateral Sclerosis
A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS
This is a phase I, multicentre randomised, double-blind, placebo-controlled trial to assess the safety and tolerability of continuous i.c.v.
- Trial name
- NCT01999803
- Testing
- sNN0029
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 15 people
- Sponsor
- Newron Sweden AB
MND (Motor Neurone DIsease)
Telehealth in MND-Research (TIM-R): A Research Database for MND
The aim of this study is to implement the Telehealth in MND system as a research database allowing people with MND to take part in research and provide data remotely (TiM-Research).
- Trial name
- TIM-R (NCT07132879)
- Testing
- No intervention - Prospective cohort study
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Sheffield
ALS (Amyotrophic Lateral Sclerosis)
Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS.
This project aims to develop a smart communication system for patients with amyotrophic lateral sclerosis (ALS), especially for stage 3 and stage 4 (late stage).
- Trial name
- NCT03787420
- Testing
- communication system
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Amyotrophic Lateral Sclerosis, ALS
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).
- Trial name
- NCT05163886
- Testing
- LAM-002A
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- IRulya Therapeutics Inc.
Foot Drop, Thigh Muscles Weakness (Hamstrings or Quadriceps)
Evaluation of the Safety and Performance of the NESS L300 Plus System
The study is designed to evaluate the safety and efficacy of using the L300 Plus as a neuroprosthesis device for walking in patients following an UMN injury or disease.
- Conditions
- Foot Drop, Thigh Muscles Weakness (Hamstrings or Quadriceps), Upper Motor Neuron Injury or Disease
- Trial name
- L300Plus (NCT01237860)
- Testing
- NESS L300 Plus System
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Bioness Inc
Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS
This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral…
- Trial name
- TUDCA-ALS (NCT03800524)
- Testing
- Tauroursodeoxycholic Acid
- Where
- 25 sites in Belgium, France and 5 more
- Volunteers
- 337 people
- Sponsor
- Humanitas Mirasole SpA
Amyotrophic Lateral Sclerosis
Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS)
Recent evidence implicates abnormalities of autonomic function in ALS including problems with gastrointestinal (GI) motility. GI complaints reported by ALS patients such as constipation, diffuse abdominal pain, and a feeling of…
- Trial name
- GIDysmotility (NCT00714805)
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Christine Barr
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
IC14 for Treatment of Amyotrophic Lateral Sclerosis
Fifty patients with amyotrophic lateral sclerosis that is progressing rapidly will be randomized to receive either the monoclonal antibody IC14 or placebo to be given intravenously over two hours twice weekly for 12 weeks.
- Trial name
- NCT03508453
- Testing
- IC14
- Where
- Australia
- Sponsor
- Implicit Bioscience
Amyotrophic Lateral Sclerosis, ALS
Open Label Extension Study of AMX0035 in Patients With ALS
This extension study, in which all participants received active treatment (AMX0035), was designed to assess the longer-term safety and therapeutic potential of AMX0035 for participants who have completed the Main Study (AMX3500…
- Trial name
- CENTAUR-OLE (NCT03488524)
- Testing
- AMX0035
- Where
- 24 sites in United States
- Volunteers
- 90 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment
To compensate for insufficiency of diagnostic tools, the present study propose to look for the predictive factors of an early fitting by noninvasive ventilation.
- Trial name
- PREDAPP (NCT03452618)
- Testing
- diagnosis variables
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Toulouse
Amyotrophic Lateral Sclerosis
The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis
Patients with Amyotrophic Lateral Sclerosis (ALS) typically endure a progressive paralysis due to the continued loss of motoneurons that leads them to death in less than 5 years. No treatment has changed its natural history.
- Trial name
- NCT01494480
- Testing
- stem cell transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Spinal Cord Injuries
Mirror Neuron Network Based Motor Imagery Training to Improve Brain Computer Interface Performance in Spinal Cord Injury Patients
The overall vision of this proposal is to demonstrate that a virtual reality based motor imagery training program will improve brain computer interface (BCI) performance and motor function in quadriplegic subjects.
- Trial name
- BCI (NCT03098927)
- Testing
- Motor imagery training
- Where
- United States
- Sponsor
- The Cleveland Clinic
Amyotrophic Lateral Sclerosis (ALS)
Extension Study of Participants From SPG302-ALS-001
This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)
- Trial name
- NCT06903286
- Testing
- SPG302
- Where
- 3 sites in Australia
- Volunteers
- 16 people
- Sponsor
- Spinogenix
Amyotrophic Lateral Sclerosis
Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
In this Phase 1 adult symptomatic patients with amyotrophic lateral sclerosis (ALS) carrying a superoxide dismutase 1 (SOD1) gene mutation thought to be causative of ALS, will receive single ascending doses of ARO-SOD1…
- Trial name
- NCT05949294
- Testing
- ARO-SOD1 Injection
- Sponsor
- Arrowhead Pharmaceuticals
Amyotrophic Lateral Sclerosis (ALS)
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
The study is being conducted to determine if DPS treatment for people with ALS and hypoventilation is associated with improved survival or diaphragm function.
- Trial name
- DPS in ALS (NCT01938495)
- Testing
- NeuRx® Diaphragm Pacing System™ (DPS)
- Where
- 25 sites in United States
- Volunteers
- 52 people
- Sponsor
- Barrow Neurological Institute
Amyotrophic Lateral Sclerosis
Stratification of Presymptomatic Amyotrophic Lateral Sclerosis: the Development of Novel Imaging Biomarkers
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder with no effective disease-modifying therapies at present. The disease is sporadic in 90 % of the ALS patients.
- Trial name
- STRATALS (NCT05358431)
- Testing
- Neuroimaging and electrophysiology
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis
Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to comprehensively investigate and analyze the home care needs and status quo of ALS patients in China, and to clarify their home care needs and status quo, so as to provide reference for the…
- Trial name
- NCT04953481
- Testing
- survey
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Peking University Third Hospital
Stroke
Action Observation, Imagery and Execution for Stroke Rehabilitation
The specific study aims will be: 1. To investigate the short- and long-term treatment effects of action observation, imagery, and execution therapy (AOIE) compared with an action observation therapy (AO) group and a control…
- Trial name
- NCT03246139
- Testing
- Action observation, imagery & execution, Action observation, Control treatment
- Where
- 4 sites in Taiwan
- Volunteers
- 17 people
- Sponsor
- Chang Gung Memorial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.